Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Celltrion Plans $513 Million Wuhan Biologics Facility; 18 Biologic Launches in China by 2030

publication date: Jan 21, 2020

Celltrion, a South Korea biopharma, plans to build a $513 million China biologics manufacturing facility in Wuhan. The company said the plant's 120,000 liter capacity will make it the largest facility in China. Last summer, Celltrion announced it would form a China JV with Nan Fung Group of Hong Kong to develop three Celltrion biosimilars in China and build a manufacturing facility. That partnership fell apart. Now, Celltrion has signed a contract with Wuhan's government to help finance its China operations. Celltrion Chairman Jung-jin Seo said the company plans to launch 18 biologic products in China by 2030. More details....

Stock Symbol: (KRX: 068270)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.